This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Huntington's disease (HD)	Histone deacetylase 3 (HDAC3); huntingtin (HTT)	Cell culture studies suggest HDAC3 inhibitors could help treat HD. In rat and mouse neurons expressing mutant HTT, <i>Hdac3</i> deficiency increased survival compared with normal <i>Hdac3</i> expression. Ongoing work includes generating <i>Hdac3</i> -deficient mouse models of HD and testing RG2833, an HDAC3 inhibitor from Repligen Corp., in cell culture models of HD. RG2833 is in Phase I testing to treat ataxia.	Unpatented; unlicensed	Bardai F.H. <i>et al. J. Neurosci.</i> ; published online July 17, 2013; doi:10.1523/JNEUROSCI.5831-12.2013 Contact: Santosh R. D'Mello, University of Texas at Dallas, Richardson, Texas e-mail: dmello@utdallas.edu
SciBX 6(31); doi:10.1038/scibx.2013.829 Published online Aug. 15, 2013				